Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for that Doze.
I and others have said before, that there are some who can see and interpret the bigger picture and some who can't. Even if we (certainly I) can't fully understand every snippet of research that appears on the BB, at least we can see that each of the snippets helps to fill in the missing bits of the bigger picture. It would be stating the obvious to say that there is clearly way more to Avacta than the current Covid excitement (and long may that continue btw) but what I do think we can now see, is that the 'bigger picture' is getting bigger all the time.
I do feel that investment returns aside, we are witnessing something quite awesome developing here. Genuinely disruptive. Dr Smith's ambitions to put Avacta up there with the likes of Roche, AZ et al, are beginning to look pretty achievable and perhaps in the space of just a few years. Mind boggling.
You flatter me Apre....just for you I have had a search to back up my thoughts. The affimer seems to conjugate with the neonatal FcRn and combined with a therapy for-say the covid damaged lung helps regrow/replace tissue/cells therefore extending half-life by 2? 3? 4? days or maybe weeks before next treatment. https://en.wikipedia.org/wiki/Neonatal_Fc_receptor
Affimers gaining traction on all fronts to benefit humanity and paid for via diagnostic LFT sales.
Hi BBB Far too technical for me to understand but did find this info on AVA04 does mention "to extend the serum half-life " ?
"Affimer biotherapeutics can be identified using phage display and easily produced at high levels in bacterial and mammalian expression systems
• The PD-L1 Affimer antagonists can be formatted in a variety of ways to generate high
affinity molecules as determined by Biacore ® and PD-1/PD-L1 competitive ELISA
• AVA04-182hFc1 was shown to be well tolerated in mice, even with repeat dosing at 10
mg/kg in the syngeneic model
• AVA04-182hFc1 inhibited tumour growth in the CT-26 syngeneic model
• This work demonstrates that the Affimer technology has the necessary properties for a therapeutic platform: generation of high affinity binding proteins that can be formatted
to extend the serum half-life and blockade a biologically relevant disease pathway in viv
https://avacta.com/wp-content/uploads/2019/10/POS014-Fc-Fusion-PD-L1-Mouse.pdf
https://avacta.com/wp-content/uploads/2019/10/POS010-Generation-of-Potent-Human-and-Mouse-PD-L1-Antagonists.pdf
I checked (should of done before posting) and Neil Bell talks about a different candidate they’ve identified through the AVA 6000 development. I’m sure I’ve seen AVA04 mentioned before though, so I wonder what it’s targeting?
Great find Bella - stuff like this is why I still read this board! Thanks for your efforts.
If you look at the drawings, it says they’ve been testing “AVA04-FcRn binding AFFIMER®fusion”.
I haven’t double checked, but I’m sure they discussed AVA04 in the presentation on Monday as a new clinical candidate?
Great find Bella - stuff like this is why I still read this board! Thanks for the efforts.
If you have a look at the attached drawings, it’s looks like they have been working with AVA04 - I haven’t checked, but I’m sure they discussed this in the presentation this week and said they’d developed AVA04 as a new drug??
GMCC - I think it is a really positive sign that, since this partnership announcement RNS Dec 18, LG patented the invention during 2021 - thus would appear they have a breakthrough = very positive for avacta and those future milestone payments (and proof of concept for Affimers)
Good Morning As highlighted by others perhaps getting close to first clinical trials for testing affimers in humans . Anyway good evidence that Avacta scientists working away in the background on therapeutics development that we hear very little about .
RNS dated 10 Dec 2018 "such as serum half-life and tissue localization"
LG patent "12] A further object of the present invention is to provide a use of the polynucleotide for increasing serum half-life of a therapeutic molecule.
Advantageous Effects of Invention
[13] The present disclosure is based on the generation of AFFIMER® polypeptides that bind to human neonatal Fc receptor (FcRn) to extend, in a controlled manner, the serum half-life of any other therapeutic molecules ( e.g., therapeutic AFFIMER® polypeptide, protein, nucleic acid, or drug) to which it is conjugated."
The present disclosure is based on the generation of AFFIMER® polypeptides that bind to human neonatal Fc receptor (FcRn) to extend, in a controlled manner, the serum half-life of any other therapeutic molecules ( e.g., therapeutic AFFIMER® polypeptide, protein, nucleic acid, or drug) to which it is conjugated.
-------------------------
RNS dated 10 Dec 2018 : Aditionally, the agreement provides that Avacta and LG Chem will collaborate jointly in the development of two different Affimer® PK/ADME modifiers – Affimers that can be fused to other therapeutic proteins to modify certain properties of those biological drug moieties such as serum half-life and tissue localization. Both parties will have the right to develop PK/ADME modified products, and by exercise of an option, to take exclusive responsibility for the development, manufacture and commercialisation of those products.
This multi-target therapeutics development agreement provides upfront and near-term milestone payments, plus longer-term clinical development milestones. Avacta will also receive royalties on any future product sales and LG Chem will cover Avacta’s costs of research and development associated with the collaboration. Avacta may receive additional option fees and milestone payments should LG Chem elect to exercise their options for additional targets.
https://avacta.com/avacta-and-lg-chem-life-sciences-agree-multi-target-affimer-therapeutics-development-alliance/
Great find many thanks for sharing .
Note Avacta employees mentioned as inventors .
(72) Inventor(s):
KIM, Yeonchul; 128, Yeoui-daero, Yeongdeungpo-gu, Seoul 07336 (KR)
LEE, Jaehyung; 128, Yeoui-daero, Yeongdeungpo-gu, Seoul 07336 (KR)
JUNG, Saem; 128, Yeoui-daero, Yeongdeungpo-gu, Seoul 07336 (KR)
LEE, Joon Hee; 128, Yeoui-daero, Yeongdeungpo-gu, Seoul 07336 (KR)
PARK, Gyeong Hyae; 128, Yeoui-daero, Yeongdeungpo-gu, Seoul 07336 (KR)
NA, Kyubong; 128, Yeoui-daero, Yeongdeungpo-gu, Seoul 07336 (KR)
MATTHEW, Vincent; 12 Quimby Lane, Amesbury, Massachusetts 01913 (US)
AMRIK, Basran; 42,Beaumont Rd, Cambridge, Cambridgeshire CB1 8PY (GB)
EMMA, Stanley; 65 West Hill, Hitchin, Hertfordshire SG5 2HY (GB)
EMMA, Jenkins; 47 Brook Road, Stansted, Essex CM24 8BB (GB)
ESTELLE, Adam; 2 Capswell court, Hitchin, Hertfordshire SG51ET (GB)
https://patentscope.wipo.int/search/docs2/iasr/WO2021075930/pdf/_pPfdgwzph0_7k7_d7csaUDvl_32Prh3NZ2t2XxGQksn54yeQXAovtdQbl34zz_D-l4tuQfy5EJY-AuPCzb0Dg8yvSlaq-1ugpHfAvjRKrWtG_OsORZIpRkpgMP415oC
Macromolecular protein and peptide therapeutics have been proven to be effective in treating critical human diseases precisely. Thanks to biotechnological advancement, a huge number of proteins and peptide therapeutics were made their way to pharmaceutical market in past few decades. However, one of the biggest challenges to be addressed for protein therapeutics during clinical application is their fast degradation in serum and quick elimination owing to enzymatic degradation, renal clearance, liver metabolism and immunogenicity, attributing to the short half-lives. Size and hydrophobicity of protein molecules make them prone to kidney filtration and liver metabolism. On the other hand, proteasomes responsible for protein destruction possess the capability of specifically recognizing almost all kinds of foreign proteins while avoiding any unwanted destruction of cellular components. At present almost all protein-based drug formulations available in market are administered intravenously (IV) or subcutaneously (SC) with high dosing at frequent interval, eventually creating dose-fluctuation-related complications and reducing patient compliance vastly.
How do you begin to evaluate how a patent like that might be monetized and what it might be worth?
I've no idea but all ears.
From what I can gather from reading the text lg must be close to trailing the Affimer in human.
Very impressive posts, Bella and Radiagreen. Thank you.
I have to say, a person can think themselves quite bright and well-informed . . . and then you read things like that. Man but those boffins are clever. As a layman, I'm getting the Affimers used "in humans" idea but I have to admit I don't fully understand all the implications.
On a more sanguine note, how do you begin to evaluate how a patent like that might be monetized and what it might be worth?
One for you chaps perhaps . . . Doze, Ophidian, Ben to the power of four et al . . . no, baby beta, not you. Please not you . . .
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021075930&tab=FULLTEXT
Background Art
[3]
The neonatal Fc receptor (FcRn) binds with high affinity to IgG and albumin through non-overlapping sites at a mildly acidic pH ( e.g., 5.0-6.5); however, it does not bind IgG or albumin at neutral pH. FcRn expression has been detected nearly ubiquitously in a number of tissues, including epithelial cells, endothelial cells, and cells of hematopoietic origin. It facilitates monitoring of IgG and serum albumin turnover, as its expression is upregulated in response to the proinflammatory cytokine, TNF-a and downregulated in response to IFN-? FcRn has been used therapeutically to shuttle biologics across mucosal surfaces in order to improve drug absorption or distribution.
[4]
Disclosure of Invention
Technical Problem
[5]
The neonatal Fc receptor (FcRn) binds with high affinity to IgG and albumin through non-overlapping sites at a mildly acidic pH (e.g., 5.0-6.5); however, it does not bind IgG or albumin at neutral pH.
[6]
Solution to Problem
[7]
An object of the present invention is to provide a polypeptide comprising an FcRn binding AFFIMER® sequence that binds to human FcRn.
[8]
Another object of the present invention is to provide a pharmaceutical preparations.
[9]
Another object of the present invention is to provide a methods that comprise administering to a subject having an autoimmune disease and/or an inflammatory disease.
[10]
Another object of the present invention is to provide a provide methods of increasing serum half-life of a therapeutic molecule.
[11]
Another object of the present invention is to provide a use of the polynucleotide for targeting FcRn.
[12]
A further object of the present invention is to provide a use of the polynucleotide for increasing serum half-life of a therapeutic molecule.
Advantageous Effects of Invention
[13]
The present disclosure is based on the generation of AFFIMER® polypeptides that bind to human neonatal Fc receptor (FcRn) to extend, in a controlled manner, the serum half-life of any other therapeutic molecules ( e.g., therapeutic AFFIMER® polypeptide, protein, nucleic acid, or drug) to which it is conjugated.
Thanks
Thanks Bella
10.WO/2021/075930
NEONATAL FC RECEPTOR BINDING AFFIMERS
WO - 22.04.2021
Int.Class
C07K 16/28
Appl.No PCT/KR2020/014207
Applicant LG CHEM, LTD.
Inventor KIM, Yeonchul
Provided herein, in some embodiments, are AFFIMER® polypeptides that binds to the neonatal Fc receptor (FcRn) and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are compositions containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.